Matrix for transdermal drug delivery

• US 7,097,853 B1
• Filed: 11/12/1997
• Issued: 08/29/2006
• Est. Priority Date: 09/14/1994
• Status: Expired due to Fees

• Current Assignee: 3M Innovative Properties Company (3M Company)
• Original Assignee: 3M Innovative Properties Company (3M Company)
• Inventors: Ko, Chan U., Duan, Daniel C., Moore, Cheryl L., Keister, Jamieson C., Garbe, James E.
• Primary Examiner(s): Webman, Edward J.
• Application Number:
  US08/968,519
• Time in Patent Office: 3,212 Days
• Field of Search: 526/328, 526/328.5, 526/329.2, 526/329.7, 525/301, 525/308, 525/309, 525/303, 524/560, 524/561, 424/448, 424/449, 428/447, 428/483
• US Class Current: 424/449
• CPC Class Codes: A61K 9/7053 obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• CPC Class Codes: A61K 9/7061 Polyacrylates
• CPC Class Codes: C08F 290/04 Polymers provided for in subclasses C08C or C08F
• CPC Class Codes: C09J 155/005 Homopolymers or copolymers obtained by polymerisation of macromolecular compounds terminated by a carbon-to-carbon double bond

Abstract

A transdermal drug delivery device involving a macromonomer-containing acrylate or methacrylate copolymer, a softener, and a drug. Also a pressure sensitive skin adhesive involving a macromonomer containing acrylate or methacrylate copolymer and a softener.

Claims

1. A transdermal drug delivery device, comprising:

(1) a backing;

(2) a matrix adhered to one side of the backing and comprising

(a) a copolymer comprising

(i) one or more A monomers selected from the group consisting of alkyl acrylates containing 4 to 10 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 10 carbon atoms in the alkyl group; and

(ii) optionally one or more ethylenically unsaturated B monomers copolymerizable with the A monomer; and

(iii) a macromonomer comprising an ethylenically unsaturated group copolymerizable with the A and B monomers defined above and having a molecular weight in the range 500-500,000;

(b) a softener dissolved in the copolymer; and

,

(c) if the softener is not therapeutically effective, a therapeutically effective amount of a drug,

 

wherein the structure and amount of the comonomers in the copolymer, the inherent viscosity of the copolymer, and the amount and structure of the drug and the softener are such as to provide the matrix with a compliance value in the range of about 2×

10<sup>−

6</sup> cm²/dyne to about 4×

10<sup>−

3</sup> cm²/dyne.

2. A transdermal drug delivery device according to claim 1, wherein the B monomer or monomers comprises a functional group selected from the group consisting of carboxylic acid, carboxylic acid ester, hydroxy, sulfonamide, urea, carbamate, carboxamide, amine, oxy, oxo, and cyano.

3. A transdermal drug delivery device according to claim 1, wherein the B monomer or monomers are selected from the group consisting of acrylic acid, methacrylic acid, maleic acid, a hydroxyalkyl acrylate containing 2 to 4 carbon atoms in the hydroxyalkyl group, a hydroxyalkyl methacrylate containing 2 to 4 carbon atoms in the hydroxyalkyl group, acrylamide, methacrylamide, an alkyl substituted acrylamide containing 1 to 8 carbon atoms in the alkyl group, diacetone acrylamide, a dialkyl acrylamide having 1 or 2 carbon atoms in the alkyl group, N-vinyl-N-methyl acetamide, N-vinyl valerolactam, N-vinyl caprolactam, N-vinyl-2-pyrrolidone, glycidyl methacrylate, alkoxyethyl acrylate containing 1 to 4 carbon atoms in the alkoxy group, alkoxyethyl methacrylate containing 1 to 4 carbon atoms in the alkoxy group, 2-ethoxyethoxyethyl acrylate, furfuryl methacrylate, furfuryl acrylate, tetrahydrofurfuryl acrylate, tetrahydrofurfuryl methacrylate, propylene glycol monomethacrylate, propylene glycol monoacrylate, polyethylene glycol acrylate, polyethylene glycol methacrylate, polyethylene glycol methyl ether acrylate, polyethylene oxide methyl ether acrylate, di(lower)alkylamino ethyl acrylate, di(lower)alkylamino ethyl methacrylate, di(lower)alkylaminopropyl methacrylamide, acrylonitrile, methacrylonitrile, and vinyl acetate.

4. A transdermal drug delivery device according to claim 1, wherein the A monomer is present in an amount of about 40 to about 95 percent by weight, based on the total weight of all monomers in the copolymer.

5. A transdermal drug delivery device according to claim 1, wherein the A monomer is present in an amount of about 50 to about 70 percent by weight, based on the total weight of all monomers in the copolymer.

6. A transdermal drug delivery device according to claim 1, wherein the A monomer is selected from the group consisting of isooctyl acrylate, 2-ethylhexyl acrylate, butyl acrylate, and cyclohexyl acrylate.

7. A transdermal drug delivery device according to claim 1, wherein the B monomer is present in an amount from 0 to 60 percent by weight based on the total weight of the copolymer.

8. A transdermal drug delivery device according to claim 1, wherein the B monomer is present in an amount of greater than 25 percent by weight based on the total weight of the copolymer, to about 50 percent by weight based on the total weight of the copolymer.

9. A transdermal drug delivery device according to claim 1, wherein the B monomer is selected from the group consisting of hydroxyethyl acrylate, hydroxyethyl methacrylate, glyceryl acrylate, N,N-dimethyl acrylamide, 2-ethoxyethoxyethyl acrylate, 2-ethoxyethyl acrylate, tetrahydrofurfuryl acrylate, acrylic acid, acrylamide, and vinyl acetate.

10. A transdermal drug delivery device according to claim 1, wherein the macromonomer has a molecular weight in the range 5,000-30,000.

11. A transdermal drug delivery device according to claim 1, wherein the macromonomer is present in an amount of not more than about 15% by weight based on the total weight of all monomers in the copolymer.

12. A transdermal drug delivery device according to claim 1, wherein the macromonomer is present in an amount of not more than about 5% by weight based on the total weight of all monomers in the copolymer.

13. A transdermal drug delivery device according to claim 1, wherein the macromonomer is a compound of the formula

wherein X is a moiety comprising an ethylenically unsaturated group copolymerizable with the A and B monomers, R² is a hydrogen atom or a lower alkyl group, R³ is a lower alkyl group or the residue of a free-radical initiator, n is an integer from 20 to 500 and each R⁴ is a monovalent radical independently selected from the group consisting of

—

CN, and —

CO₂R⁶ wherein R⁵ is a hydrogen atom or a lower alkyl group, and R⁶ is a lower alkyl group.

14. A transdermal drug delivery device according to claim 1, wherein the macromonomer is selected from the group consisting of polymethylmethacrylate macromonomer, styrene/acrylonitrile macromonomer, and polystyrene macromonomer.

15. A transdermal drug delivery device according to claim 1, wherein the softener is present in an amount in excess of 20% and less than about 60% by weight based on the total weight of the matrix.

16. A transdermal drug delivery device according to claim 1, wherein the softener is selected from the group consisting of C₈-C₂₂ fatty acids, C₈-C₂₂ fatty alcohols, lower alkyl esters of C₈-C₂₂ fatty acids, monoglycerides of C₈-C₂₂ fatty acids, di(lower)alkyl esters of C₆-C₈ diacids, tetrahydrofuryl alcohol polyethylene glycol ether, polyethylene glycol, propylene glycol, ethoxyethoxy ethanol, diethylene glycol monomethyl ether, N,N-dimethyl dodecylamine-N-oxide, 2-(2-ethoxyethoxy)ethanol, and combinations of the foregoing.

17. A transdermal drug delivery device according to claim 1, wherein the softener is selected from the group consisting of dimethyl sulfoxide, glycerol, ethanol, ethyl acetate, acetoacetic ester, N-methyl pyrrolidone, isopropyl alcohol, alkylaryl ethers of polyethylene oxide, polyethylene oxide monomethyl ethers, and polyethylene oxide dimethyl ethers.

18. A transdermal drug delivery device according to claim 1, wherein the softener is selected from the group consisting of nicotine, nitroglycerine, chlorpheniramine, nicotinic acid benzyl ester, orphenadrine, scopolamine, and valproic acid.

33. The transdermal drug delivery device of claim 1 wherein the softener is selected from the group consisting of nicotine, nitroglycerine, chlorpheniramine, nicotinic acid benzyl ester, orphenadrine, scopolamine, valproic acid and mixtures thereof.

19. A pressure sensitive skin adhesive comprising:

(1) a copolymer comprising

(a) one or more A monomers selected from the group consisting of alkyl acrylates containing 4 to 10 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 10 carbon atoms in the alkyl group; and

(b) optionally one or more ethylenically unsaturated B monomers copolymerizable with the A monomer; and

(c) a macromonomer comprising an ethylenically unsaturated group copolymerizable with the A and B monomers defined above and having a molecular weight in the range 500-500,000; and

(2) a softener dissolved in the copolymer,

 

wherein the structure and amount of the comonomers in the copolymer, the inherent viscosity of the copolymer, and the amount and structure of the softener are such as to provide the pressure sensitive sldn adhesive with a compliance value in the range 2×

10<sup>−

6</sup> cm²/dyne to about 4×

10<sup>−

3</sup> cm²/dyne.

20. A pressure sensitive skin adhesive according to claim 19, wherein the B monomer or monomers comprise a functional group selected from the group consisting of carboxylic acid, carboxylic acid ester, hydroxy, sulfonamide, urea, carbamate, carboxamide, amine, oxy, oxo, and cyano.

21. In atransdermal delivery system for administering at least one pharmacologically active agent comprising a flexible backing material impermeable to said active agent and an adhesive layer on said backing material, the improvement wherein said adhesive layer comprises a pressure sensitive adhesive composition comprised of (1) a percutaneous penetration enhancer to increase permeability of skin to transdermally administered pharmacologically active agents in admixture with (2) a macromer reinforced base polymer, said base polymer component comprising a phase separated graft copolymer comprised of copolymerized monomers A and B to form a backbone polymer having polymeric moieties grafted thereto, wherein monomer A is a monomeric acrylic or methacrylic ester of a non-tertiary alcohol having from 4 to 10 carbon atoms, and monomer B is a polar monomer which is copolymerizable with monomer A, said percutaneous penetration enhancer being present in said composition in an amount of up to 40 percent by weight based on the weight of the composition.

22. The delivery system of claim 21 wherein said graft polymeric moiety is a polymerized monoalkenyl-substituted aromatic hydrocarbon.

23. The delivery system of claim 22 wherein said polymerized monoalkenyl-substituted aromatic hydrocarbon comprises polystyrene.

24. The delivery system of claim 21 wherein the molecular weight of said graft polymeric moiety is in the range of from about 500 to 500,000.

25. The delivery system of claim 21 wherein said B monomer is selected from the group consisting of acrylic acid, methacrylic acid, acrylamide, methylacrylamide, acrylonitrile and methacrylonitrile.

26. The delivery system of claim 21 wherein said base polymer comprises from about 40 to 95 percent by weight of said A monomer.

27. The delivery system of claim 26 wherein said base polymer comprises from about 50 to 70 percent by weight of said A monomer.

28. The delivery system of claim 21 wherein said graft polymeric moiety comprises poly-alpha-methylstyrene.

29. The delivery system of claim 21 wherein said percutaneous penetration enhancer is present in said composition in an amount in the range of from 5 to 30 percent by weight.

30. A transdermal drug delivery device, comprising:

(1) a backing;

(2) a matrix adhered to one side of the backing and comprising

(a) a copolymer comprising

(i) one or more A monomers selected from the group consisting of alkyl acrylates containing 4 to 10 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 10 carbon atoms in the alkyl group; and

(ii) optionally one or more ethylenically unsaturated B monomers copolymerizable with the A monomer; and

(iii) a macromonomer comprising an ethylenically unsaturated group copolymerizable with the A and B monomers defined above; and

(3) a skin penetration enhancer dissolved in the copolymer.

31. A pressure sensitive skin adhesive comprising:

(1) a copolymer comprising

(a) one or more A monomers selected from the group consisting of alkyl acrylates containing 4 to 10 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 10 carbon atoms in the alkyl group; and

(b) optionally one or more ethylenically unsaturated B monomers copolymerizable with the A monomer; and

(c) a macromonomer comprising an ethylenically unsaturated group copolymerizable with the A and B monomers defined above; and

(2) a skin penetration enhancer dissolved in the copolymer.

32. A transdermal drug delivery device, comprising:

(1) a backing;

(2) a matrix adhered to one side of the backing and comprising

(a) a copolymer comprising

(i) one or more A monomers selected from the group consisting of alkyl acrylates containing 4 to 10 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 10 carbon atoms in the alkyl group; and

(ii) optionally one or more ethylenically unsaturated B monomers copolymerizable with the A monomer; and

(iii) a macromonomer comprising an ethylenically unsaturated group copolymerizable with the A and B monomers defined above; and

(3) a softener dissolved in the copolymer,

 

wherein the structure and amount of the comonomers in the copolymer, the inherent viscosity of the copolymer, and the amount and structure of the softener are such as to provide the pressure sensitive skin adhesive with a compliance value in the range 2×

10<sup>−

6</sup> cm²/dyne to about 1×

10<sup>−

3</sup> cm²/dyne.

34. The transdermal drug delivery device of claim 32 wherein the softener is selected front the group consisting of nicotine, nitroglycerine, chlorpheniramine, nicotinic acid benzyl ester, orphenadrine, scopolamine, valproic acid and mixtures there.